The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...

Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...

City Therapeutics’ Series B syndicate added Viking Global and Sofinnova, with continued support from multiple crossover and strategic investors, signaling broad buy-side confidence in RNAi platform ...

AstraZeneca ($18.5B), BMS ($15.2B), and Pfizer ($10.5B) anchored early-2026 China partnering, reflecting a structural shift from ~5% of licensing four years ago to a majority today. China dealmaking ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

Contributing factors include genetic predisposition, stress, nutritional deficiencies, autoimmune or thyroid disorders, ...

Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...

FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...

Deal terms for Vega include $1.25B upfront and up to $750M sales milestones, with expected close in Q3 2026 and a projected $1.25B R&D charge. VGA039 aims to improve hemostasis via Protein S ...

On Sunday, Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented data on pancreatic cancer that is moving the field ...

The 9-0 decision, authored by Justice Ketanji Brown Jackson, overturned a previous lower appellate court ruling that had ...